for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

武田薬品工業株式会社

4502.T

現在値

3,762.00JPY

変化

-25.00(-0.66%)

出来高

3,687,600

本日のレンジ

3,755.00

 - 

3,783.00

52週レンジ

2,993.00

 - 

3,842.00

∙ 約20分前の相場を表示しています。

適時開示

Ovid Therapeutics- On May 10, Takeda Notified Co Takeda Planned To Announce Two Pivotal Phase 3 Programs Evaluating Soticlestat Are Likely To Be Delayed

May 11 (Reuters) - Ovid Therapeutics Inc <OVID.O>::OVID THERAPEUTICS- ON MAY 10, TAKEDA NOTIFIED CO TAKEDA PLANNED TO ANNOUNCE TWO PIVOTAL PHASE 3 PROGRAMS EVALUATING SOTICLESTAT ARE LIKELY TO BE DELAYED.OVID THERAPEUTICS INC - TAKEDA DISCLOSED IT IS WORKING ON MULTIPLE APPROACHES TO MINIMIZE DELAYS.OVID THERAPEUTICS INC - TAKEDA STATED THAT STUDIES ARE ACTIVELY RECRUITING PATIENTS AND REMAIN ONE OF TAKEDA'S HIGHEST PRIORITY, LATE-STAGE, PROGRAMS.Further company coverage: OVID.O. ((Reuters.Briefs@thomsonreuters.com;)).

FDA Approves Prophylactic Treatment With VONVENDI® [Von Willebrand Factor (Recombinant)] For Adult Patients Living With Severe Type 3 Von Willebrand Disease (VWD)

Jan 31 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::FDA APPROVES PROPHYLACTIC TREATMENT WITH VONVENDI® [VON WILLEBRAND FACTOR (RECOMBINANT)] FOR ADULT PATIENTS LIVING WITH SEVERE TYPE 3 VON WILLEBRAND DISEASE (VWD).

Takeda Receives Complete Response Letter From The U.S. FDA For TAK-721

Dec 21 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA RECEIVES COMPLETE RESPONSE LETTER FROM THE U.S. FDA FOR TAK-721.TAKEDA PHARMACEUTICAL CO LTD - CRL INDICATES FDA HAS COMPLETED ITS REVIEW OF TAK-721 NDA AND DETERMINED THAT IT CANNOT BE APPROVED IN ITS PRESENT FORM.TAKEDA PHARMACEUTICAL CO LTD - FDA RECOMMENDED AN ADDITIONAL CLINICAL STUDY IN ORDER TO HELP RESOLVE FDA FEEDBACK.TAKEDA PHARMACEUTICAL CO LTD - ASSESSING DETAILS OF CRL AND EVALUATING A REGULATORY PATH FORWARD.

Secura Bio Announces U.S. Withdrawal Of Farydak (Panobinostat) NDA

Nov 30 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::SECURA BIO ANNOUNCES U.S. WITHDRAWAL OF FARYDAK (PANOBINOSTAT) NDA.SECURA BIO - CO AND ITS PARTNERS WILL CONTINUE TO MARKET FARYDAK IN OTHER MARKETS WHERE IT HAS BEEN APPROVED.SECURA BIO - NOTED THAT IT WAS NOT FEASIBLE TO COMPLETE REQUIRED POST-APPROVAL CLINICAL STUDIES AS DESIGNED AS PART OF ACCELERATED APPROVAL PROCESS.

Adage Capital Partners Cuts Share Stake in GE and Honeywell, Ups Share Stake in J&J and Exxon Mobil

Nov 15 (Reuters) - ADAGE CAPITAL PARTNERS::ADAGE CAPITAL PARTNERS CUTS SHARE STAKE BY 32.1% IN ABBVIE TO 1.45 MILLION SHARES - SEC FILING.ADAGE CAPITAL PARTNERS CUTS SHARE STAKE BY 90.8% IN GENERAL ELECTRIC TO 1.95 MILLION SHARES - SEC FILING.ADAGE CAPITAL PARTNERS CUTS SHARE STAKE IN HONEYWELL INTERNATIONAL INC BY 68.4 PERCENT TO 83,425 SHARES.ADAGE CAPITAL PARTNERS GP LLC UPS SHARE STAKE IN JOHNSON & JOHNSON BY 25.0 PERCENT TO 2.7 MILLION SHARES.ADAGE CAPITAL PARTNERS GP LLC UPS SHARE STAKE IN EXXON MOBIL CORP BY 33.4 PERCENT TO 8.7 MILLION SHARES.ADAGE CAPITAL PARTNERS TAKES SHARE STAKE OF 694,900 SHARES IN EBAY INC. SHARES.ADAGE CAPITAL PARTNERS DISSOLVES SHARE STAKE IN TAKEDA PHARMACEUTICAL CO LTD SPONSORED ADS.ADAGE CAPITAL PARTNERS DISSOLVES SHARE STAKE IN SLACK TECHNOLOGIES INC CLASS A SHARES.ADAGE CAPITAL PARTNERS UPS SHARE STAKE IN STELLANTIS N.V TO 1.8 MILLION SHARES FROM 261,773 SHARES.ADAGE CAPITAL PARTNERS UPS SHARE STAKE IN AMGEN INC TO 169,238 SHARES FROM 38,038 SHARES.ADAGE CAPITAL PARTNERS UPS SHARE STAKE IN AT&T INC BY 18 PERCENT TO 7.3 MILLION SHARES.ADAGE CAPITAL PARTNERS GP LLC - CHANGE IN HOLDINGS ARE AS OF SEPTEMBER 30, 2021 AND COMPARED WITH THE PREVIOUS QUARTER ENDED AS OF JUNE 30, 2021.

Takeda Pharmaceutical Co To Buy Back Up To 2.23% Of Shares Worth 100 Billion Yen

Oct 28 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TO BUY BACK UP TO 2.23% OF SHARES, WORTH 100 BILLION YEN.

Takeda To Acquire Gammadelta Therapeutics To Accelerate Development Of Allogeneic ΓΔT Cell Therapies Addressing Solid Tumors

Oct 27 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA TO ACQUIRE GAMMADELTA THERAPEUTICS TO ACCELERATE DEVELOPMENT OF ALLOGENEIC ΓΔT CELL THERAPIES ADDRESSING SOLID TUMORS.

Immusoft Signs Research Collaboration And License Option Agreement With Takeda Pharmaceutical Co Ltd

Oct 13 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::IMMUSOFT - SIGNED RESEARCH COLLABORATION AND LICENSE OPTION AGREEMENT WITH TAKEDA PHARMACEUTICAL COMPANY LIMITED.IMMUSOFT - UNDER TERMS OF AGREEMENT, CO WILL RECEIVE AN UNDISCLOSED UPFRONT PAYMENT AND RESEARCH FUNDING SUPPORT.IMMUSOFT - ALSO ELIGIBLE TO RECEIVE FUTURE OPTION FEES AND MILESTONE PAYMENTS WITH A TOTAL POTENTIAL VALUE OF MORE THAN $900 MILLION.

Poseida Therapeutics Announces Research Collaboration With Takeda For Novel Non-Viral In Vivo Gene Therapies

Oct 12 (Reuters) - Poseida Therapeutics Inc <PSTX.O>::POSEIDA THERAPEUTICS ANNOUNCES RESEARCH COLLABORATION WITH TAKEDA FOR NOVEL NON-VIRAL IN VIVO GENE THERAPIES.POSEIDA THERAPEUTICS - PARTIES TO COLLABORATE TO INITIALLY DEVELOP UP TO SIX IN VIVO GENE THERAPY PROGRAMS UTILIZING CO'S NOVEL TECHNOLOGY PLATFORMS.POSEIDA THERAPEUTICS INC - TAKEDA ALSO HAS AN OPTION TO ADD TWO ADDITIONAL PROGRAMS TO COLLABORATION.POSEIDA THERAPEUTICS INC - TAKEDA IS OBLIGATED TO PROVIDE FUNDING FOR ALL COLLABORATION PROGRAM RESEARCH AND DEVELOPMENT COSTS.POSEIDA THERAPEUTICS INC - WILL RECEIVE AN UPFRONT PAYMENT OF $45 MILLION.POSEIDA THERAPEUTICS - WILL RECEIVE PRECLINICAL MILESTONES THAT TOGETHER COULD POTENTIALLY EXCEED $125 MILLION, IF MILESTONES FOR 6 PROGRAMS ARE ACHIEVED.POSEIDA - ELIGIBLE TO GET FUTURE MILESTONE PAYMENTS WITH POTENTIAL VALUE OF UP TO $2.7 BILLION IF MILESTONES FOR 6 PROGRAMS ARE ACHIEVED.POSEIDA THERAPEUTICS INC - ELIGIBLE TO RECEIVE UP TO $3.6 BILLION IF MILESTONES RELATED TO TWO OPTIONAL PROGRAMS ARE ALSO ACHIEVED.

Takeda Pharmaceutical Co Ltd Partners With Takeda To Develop Maralixibat For Rare Pediatric Liver Diseases In Japan

Sept 21 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::MIRUM PHARMACEUTICALS AND TAKEDA ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO DEVELOP AND COMMERCIALIZE MARALIXIBAT FOR RARE PEDIATRIC LIVER DISEASES IN JAPAN.MIRUM PHARMACEUTICALS INC - TAKEDA WILL BE RESPONSIBLE FOR REGULATORY APPROVAL AND COMMERCIALIZATION OF MARALIXIBAT IN JAPAN.MIRUM PHARMACEUTICALS INC - TAKEDA WILL ALSO BE RESPONSIBLE FOR DEVELOPMENT, INCLUDING CONDUCTING CLINICAL STUDIES IN CHOLESTATIC INDICATIONS..

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up